John joined the AMR Action Fund after 20+ years at Pfizer, where he was involved in multiple facets of antibiotic drug development and commercialization. He contributed to shaping the world’s first subscription model for antibiotics and worked on several other innovative contracts during his tenure with Pfizer. Immediately prior to joining the Fund, he was the Vice President of Patient and Health Impact for Pfizer’s Hospital business unit, which consisted of a portfolio of over 170 molecules, including 50 medicines on the WHO’s Essential Medicines List, and dozens of anti-infective and anti-fungal drugs as well as ten drug delivery systems. The work of John’s team encompassed pricing, access, reimbursement, health economics, outcomes research and real world data collection and evidence. He holds an MBA from George Mason University and a BS from Villanova University and served six years in the U.S. Navy.